慢性肾脏病合并2型糖尿病患者快速同步启动指南导向肾脏治疗
全球慢性肾脏病发病率持续上升,2型糖尿病是主要贡献因素。慢性肾脏病合并2型糖尿病患者心血管风险升高,心血管死亡风险高于进展至肾衰竭。指南倡导的「四大支柱」治疗包括肾素-血管紧张素系统抑制剂、钠-葡萄糖协同转运蛋白2抑制剂、非甾体盐皮质激素受体拮抗剂和胰高血糖素样肽-1受体激动剂,可降低心血管-肾脏风险。本文旨在综述指南推荐治疗的安全性证据,并讨论快速序贯启动这些治疗在慢性肾脏病患者中的挑战。
要点
- 慢性肾脏病合并2型糖尿病患者心血管死亡风险高于进展至肾衰竭。
- 指南倡导「四大支柱」治疗以降低心血管-肾脏风险。
- 快速序贯启动四大支柱治疗的安全性数据有限,尚需进一步研究。
核心结论
- 本文旨在综述指南推荐治疗的安全性证据,并讨论在慢性肾脏病患者中快速序贯启动这些治疗的挑战。
- 在慢性肾脏病背景下同时启动全部四种治疗尚未经过测试,因为缺乏该高风险人群的安全性和耐受性数据。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 全球慢性肾脏病发病率持续上升,2型糖尿病是主要贡献因素。
- 慢性肾脏病合并2型糖尿病患者心血管风险升高,心血管死亡可能性大于进展至肾衰竭。
- 指南倡导的「四大支柱」治疗包括肾素-血管紧张素系统抑制剂、钠-葡萄糖协同转运蛋白2抑制剂、非甾体盐皮质激素受体拮抗剂和胰高血糖素样肽-1受体激动剂。
- 这些治疗单独使用时虽可减轻心血管和肾脏事件,但在分别测试这些治疗的主要临床试验及真实世界临床环境中,这些事件的残余风险仍然很高。
- 快速序贯启动这些治疗的安全性数据仍然有限。
关键数值与推荐
- 指南倡导的「四大支柱」治疗包括肾素-血管紧张素系统抑制剂、钠-葡萄糖协同转运蛋白2抑制剂、非甾体盐皮质激素受体拮抗剂和胰高血糖素样肽-1受体激动剂,以降低心血管-肾脏风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 在慢性肾脏病背景下同时启动全部四种治疗尚未经过测试,因为缺乏该高风险人群的安全性和耐受性数据。
- 快速序贯启动这些治疗的安全性数据仍然有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The global incidence of CKD continues to rise, with type 2 diabetes as a major contributor. At any stage of CKD, patients with concurrent CKD and type 2 diabetes are at heightened cardiovascular risk and have a greater likelihood of dying from cardiovascular causes than progressing to kidney failure. Consequently, the use of "four pillars" of CKD therapy, including renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitor, nonsteroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists, has been advocated to reduce cardiovascular-kidney risk. Although these therapies can mitigate cardiovascular and kidney events when used individually, the residual risks of these events remain high across major clinical trials testing these therapies separately as well as in real-world clinical settings. This raises the question about when to optimally initiate these therapies, including strategies that start these agents in rapid sequence, or even simultaneously, to reduce long-term risk, thereby mirroring best practices with rapid titration schedules in patients with heart failure. However, initiating all four therapies simultaneously in the setting of CKD has not yet been tested due to lack of data on safety and tolerability in this high-risk population. Data regarding the safety profile of rapid sequence initiation remain limited. Therefore, our aim was to review the existing evidence on the safety profiles of guideline-recommended therapies and discuss the challenges associated with rapid sequence initiation of these treatments in patients with CKD.
引用
- Rashid AM, Khan MS, Cherney DZI, et al. Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes. J Am Soc Nephrol. 2025. PMID: 40327845. doi:10.1681/ASN.0000000752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。